Related Experiment Video
Updated: Jun 24, 2026
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Butterfly glioma of the corpus callosum
1Department of Surgery, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe), Wardha, India. dramitagrawal@gmail.com
Abstract:
The prognosis of glioblastoma multiforme (GBM) is poor even with aggressive first-line therapy, which includes surgery, radiation therapy, and adjuvant chemotherapy. Although the ideal course of treatment for elderly patients with newly diagnosed GBM is still undecided and requires further studies, the new chemotherapeutic agents administered with or without concomitant radiation therapy have shown promising results. However, in our setting, where resources are limited and newer treatment options are expensive, it is often difficult to deliver the best care to the patient.
Insights
Glioblastoma multiforme (GBM) has a poor prognosis despite aggressive treatment. Newer chemotherapy shows promise, but resource limitations hinder optimal care, especially for elderly patients.
Area of Science:
- Neuro-oncology
- Clinical oncology
- Cancer therapy
Background:
- Glioblastoma multiforme (GBM) presents a significant therapeutic challenge with a generally poor prognosis.
- Standard first-line treatment involves surgery, radiation therapy, and adjuvant chemotherapy.
- Optimal treatment strategies for elderly GBM patients remain under investigation.
Observation:
- Newer chemotherapeutic agents demonstrate potential efficacy in GBM treatment, with or without concurrent radiation.
- The accessibility of advanced treatments is often limited in resource-constrained settings.
- High costs associated with novel therapies pose a barrier to optimal patient care.
Findings:
- Despite aggressive therapies, glioblastoma multiforme (GBM) prognosis remains poor.
- Emerging chemotherapeutic agents offer promising results for GBM patients.
- Resource limitations and high treatment costs impede the delivery of advanced care.
Implications:
- Further research is needed to establish optimal treatment protocols for elderly GBM patients.
- Innovative and cost-effective therapeutic strategies are crucial for resource-limited environments.
- Addressing financial and logistical barriers is essential for improving GBM patient outcomes.
